Journal
EXPERT REVIEW OF VACCINES
Volume 8, Issue 1, Pages 51-66Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.8.1.51
Keywords
allogenic; antigen specific; autologous; cancer vaccine; immunotherapy; progression-free survival; survival; therapeutic; whole cell
Categories
Ask authors/readers for more resources
This review elucidates state-of-the-art clinical studies on active specific immunotherapy with tumor vaccines. It refers solely to randomized studies and has a special focus on patient's survival, the most important parameter for any therapy. Of special interest, from a tumor immunological point of view, is a comparison between the results obtained with allogeneic tumor cell-derived vaccines and those obtained with autologous tumor cell-derived vaccines. Overall, autologous vaccines have given better results than allogeneic vaccines. Random mutations in cancer generate unique antigens in each individual case. The superiority of autologous vaccines suggests that unique tumor-associated antigens are particularly important in generating responsive T cells for a therapeutic effect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available